Fig. 1
From: Natural products as potential drug treatments for acute promyelocytic leukemia
Mechanisms of ATRA and ATO in the treatment of APL. The PML-RARα fusion protein inhibits the differentiation and maturation of promyelocytes through dominant-negative inhibition. ATRA degrades PML-RARα, and ATO increases mitochondrial pore permeability, resulting in the release of apoptosis-inducing factor (AIF) and cytochrome C to the outside of the mitochondria, inducing apoptosis